You are receiving this email because you are subscribed to Daily Insider Trades. If you no longer wish to receive these emails, please unsubscribe here. |
|
|
Targeting stocks with recently announced buyback programs can increase returns significantly, especially when pursued consistently over time.
With a buyback, companies may increase both earnings per share and potential upside by decreasing the total supply of outstanding shares. It can also indicate a company's confidence in their own stock value.
Here are three notable recent stock buybacks - |
Alico, Inc. – SYM: ALCO
Recent Price: $28.54
Buyback Action: The Board of Directors approved a new $50 million share repurchase program, equal to around 22% of its market cap at announcement.
Alico, Inc., together with its subsidiaries, operates as an agribusiness and land management company in the United States. The company operates in two segments: Alico Citrus, and Land Management and Other Operations. The Alico Citrus segment engages in planting, owning, and cultivating or managing citrus groves to produce fruit for sale to fresh and processed citrus markets, as well as purchasing and reselling of fruit and value-added services, which includes contracting for the harvesting, marketing, and hauling of citrus. The Land Management and Other Operations segment engages in the grazing and hunting leasing, management, and/or conservation of unimproved native pastureland, and activities related to rock mining royalties and other business; and owning or leasing of improved farmland. The company was incorporated in 1960 and is based in Fort Myers, Florida. |
This Gold Explorer May Be Perfectly Timed for Today's Market Gold is climbing, inflation is sticky, and global uncertainty is spreading-smart investors are once again looking to gold. But it's not just about bullion. One small explorer is sitting on a massive land package in North America's most productive gold belt, with what could be over 6 million ounces in resources. And they could be timing it perfectly. They've got a technical team with real credibility, a growing resource, and a key economic study on the way. Could this be the ultimate chaos hedge? [See why early investors are paying close attention] |
Conduit Pharmaceuticals Inc. – SYM: CDT
Recent Price: $0.93
Buyback Action: The Board of Directors announced that it had approved a new $1 million share repurchase program, equal to around 17.46% of its market cap at announcement.
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was founded in 2019 and is based in Naples, Florida. |
OPKO Health, Inc. – SYM: OPK
Recent Price: $1.39
Buyback Action: The Board of Directors announced that it had approved an additional $100 million share repurchase program, equal to around 9.45% of its market cap at announcement.
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. The company was founded in 2007 and is headquartered in Miami, Florida. View the full article here > |
|
|
We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of Goldshore Resources (OTC: GSHRF). The compensation consists of up to $5,000 and was received/will be received from Investing Media Solutions. This compensation should not be considered as an endorsement of the securities of adviser Goldshore Resources (OTC: GSHRF) and we are not responsible for any errors or omissions in any information provided about the securities of Goldshore Resources (OTC: GSHRF) by Edge on the Street or Investing Media Solutions. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 4/14/2025. Our mailing address is:
DC2 Publishing LLC
4260 NW 1st Avenue Suite # 55
Boca Raton, FL 33431 - 4264 Daily Insider Trades
Copyright © 2025 DC2 Publishing LLC, All rights reserved.
You're receiving this email as part of your subscription to Daily Insider Trades. For more information about our privacy practices, please review our Privacy Policy or our Terms of Use.
|
|
|
|
Post a Comment
Post a Comment